Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
- Michael Friedlander
- , Kathleen N. Moore
- , Nicoletta Colombo
- , Giovanni Scambia
- , Byoung Gie Kim
- , Ana Oaknin
- , Alla Lisyanskaya
- , Gabe S. Sonke
- , Charlie Gourley
- , Susana Banerjee
- , Amit Oza
- , Antonio González-Martín
- , Carol Aghajanian
- , William H. Bradley
- , Joyce Liu
- , Cara Mathews
- , Frédéric Selle
- , Alain Lortholary
- , Elizabeth S. Lowe
- , Robert Hettle
- University of New South Wales
- University of Oklahoma
- University of Milan - Bicocca
- IRCCS Istituto Europeo di Oncologia - Milano
- IRCCS
- Vall d'Hebron Institute of Oncology
- St Petersburg City Oncology Dispensary
- Netherlands Cancer Institute
- University of Edinburgh
- Royal Marsden NHS Foundation Trust
- Institute of Cancer Research
- Princess Margaret Cancer Centre
- University of Navarra
- Memorial Sloan-Kettering Cancer Center
- Medical College of Wisconsin
- Dana-Farber Cancer Institute
- Women and Infants Hospital of Rhode Island
- Groupe hospitalier Diaconesses Croix Saint-Simon
- Groupe D'Investigateurs Nationaux pour L'Etude des Cancers Ovariens
- Centre Catherine de Sienne Hopital privé du Confluent
- AstraZeneca
- PAREXEL International
Research output: Contribution to journal › Article › peer-review
52
Link opens in a new tab
Scopus
citations